- Home
- RIGL vs PSNL Comparison
RIGL vs PSNL Comparison
Compare RIGL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PSNL
- Stock Information
- Founded
- RIGL 1996
- PSNL 2011
- Country
- RIGL United States
- PSNL United States
- Employees
- RIGL N/A
- PSNL N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- RIGL Health Care
- PSNL Health Care
- Exchange
- RIGL Nasdaq
- PSNL Nasdaq
- Market Cap
- RIGL 486.4M
- PSNL 460.7M
- IPO Year
- RIGL 2000
- PSNL 2019
- Fundamental
- Price
- RIGL $21.81
- PSNL $5.55
- Analyst Decision
- RIGL Buy
- PSNL Strong Buy
- Analyst Count
- RIGL 5
- PSNL 4
- Target Price
- RIGL $34.80
- PSNL $8.56
- AVG Volume (30 Days)
- RIGL 347.9K
- PSNL 1.5M
- Earning Date
- RIGL 03-04-2025
- PSNL 02-26-2025
- Dividend Yield
- RIGL N/A
- PSNL N/A
- EPS Growth
- RIGL N/A
- PSNL N/A
- EPS
- RIGL 0.22
- PSNL N/A
- Revenue
- RIGL $157,374,000.00
- PSNL $87,489,000.00
- Revenue This Year
- RIGL $51.34
- PSNL $15.76
- Revenue Next Year
- RIGL $15.75
- PSNL $4.90
- P/E Ratio
- RIGL $98.50
- PSNL N/A
- Revenue Growth
- RIGL 21.65
- PSNL 24.05
- 52 Week Low
- RIGL $7.48
- PSNL $1.12
- 52 Week High
- RIGL $29.82
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- RIGL 64.53
- PSNL 54.41
- Support Level
- RIGL $17.28
- PSNL $4.70
- Resistance Level
- RIGL $18.25
- PSNL $5.50
- Average True Range (ATR)
- RIGL 1.37
- PSNL 0.57
- MACD
- RIGL 0.65
- PSNL -0.14
- Stochastic Oscillator
- RIGL 99.68
- PSNL 37.28
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.